Review
Open access
Sep 2026
Postoperative circulating tumor DNA in stage II colon cancer: biological rationale, clinical evidence, and unresolved challenges
Background Stage II colon cancer is clinically heterogeneous. Current clinicopathologic risk factors cannot accurately identify patients with residual disease after curative resection. Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for the detection of minimal residual disease (MRD), defined as micr...
Er-Hua Yang, Xue-Feng Wang, Jia-Jing Zhang et al.
· Frontiers in Oncology · 0 citations